Head-to-head · WeighScore
Gala Health vs Ondra Health
The verdict
Ondra Health takes it — 86.8/100 to 82.9/100.
Ondra Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lowest semaglutide sticker in the ranking ($93) paired with some brand-name access and LegitScript verification.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Gala Health | Ondra Health |
|---|---|---|
| WeighScore | 82.9/100 | 86.8/100 |
| Grade | B− | B |
| Site position | #12 | #7 |
| Semaglutide | Not disclosed | $93/mo |
| Tirzepatide | $179/mo (yearly subscription) | $166/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #12 · B−
Strengths
- Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
- Prices are published openly rather than quiz-gated, with all doses included at the one rate
- All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet — injection only
- Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
Site position #7 · B
Strengths
- Lowest listed semaglutide price ($93/mo)
- Some brand-name access
- LegitScript-verified, all 50 states
Where it loses points
- Tirzepatide steps up to $166/mo
- Labs/monitoring detail not published
- Compounded-first
Featured provider
Gala Health
Gala Health scores 82.9/100 (B−). A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.